- Raw materials
- Additives
- Sodium glycerophosphate
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Sodium glycerophosphate API Manufacturers & Suppliers
4 verified results
All Sodium glycerophosphate data. Full access. Full negotiation power
Commercial-scale Suppliers
Employees: 50+
All certificates
Employees: 10
All certificates
All certificates
Employees: 1000
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Sodium glycerophosphate | CAS No: 1334-74-3 | GMP-certified suppliers
A medication that provides phosphate supplementation for patients receiving total parenteral nutrition to prevent and treat hypophosphatemia in clinical settings.
Therapeutic categories
Primary indications
- Sodium glycerophosphate is indicated for use as a source of phosphate in total parenteral nutrition
- It is used in combination with amino acids, dextrose, lipid emulsions, and other electrolytes
Product Snapshot
- Sodium glycerophosphate is available primarily as injectable solutions and emulsions suitable for intravenous, intramuscular, oral, and parenteral administration
- It is used mainly as a phosphate source in total parenteral nutrition formulations
- The product is approved for use in key regulatory markets including the US and Canada
Clinical Overview
Pharmacologically, sodium glycerophosphate serves as a donor of inorganic phosphate following enzymatic hydrolysis by serum alkaline phosphatases. Upon administration, glycerophosphate is dephosphorylated to release inorganic phosphate and glycerol, with the extent of hydrolysis dependent on alkaline phosphatase activity. The liberated phosphate is essential for numerous biological processes, including energy metabolism, cell membrane integrity, and intracellular signaling.
Regarding absorption, distribution, metabolism, and excretion (ADME), sodium glycerophosphate is administered systemically via the parenteral route. As a precursor of inorganic phosphate, it bypasses gastrointestinal absorption and is directly available for metabolic use following enzymatic cleavage. The pharmacokinetic profile hinges on the rate of hydrolysis and subsequent phosphate utilization within the body.
Safety considerations for sodium glycerophosphate focus on monitoring phosphate levels to avoid complications such as hyperphosphatemia or electrolyte imbalance. Careful adjustment of dosing is critical in patients with impaired renal function to minimize toxicity risks. Potential adverse effects are generally related to the underlying electrolyte disturbances rather than the compound itself.
Sodium glycerophosphate is approved and included in various electrolyte solutions used in intravenous nutrition. It is categorized under phosphate salts and electrolyte solutions with relevance to blood and blood-forming organs and membrane lipids.
From an API sourcing perspective, high purity and consistent quality are essential to ensure safety and efficacy in parenteral nutrition applications. Compliance with pharmacopeial standards and rigorous quality control testing for phosphate content, sterility, and endotoxin levels are critical parameters for procurement decisions.
Identification & chemistry
| Generic name | Sodium glycerophosphate |
|---|---|
| Molecule type | Small molecule |
| CAS | 1334-74-3 |
| UNII | G43E72677U |
| DrugBank ID | DB09561 |
Pharmacology
| Summary | Sodium glycerophosphate serves as a phosphate donor by releasing inorganic phosphate through enzymatic hydrolysis. It is utilized primarily to supply phosphate ions essential for cellular functions during total parenteral nutrition. Its pharmacodynamic effect centers on maintaining phosphate homeostasis in patients requiring intravenous nutrient support. |
|---|---|
| Mechanism of action | Sodium glycerophosphate acts as a donor of inorganic phosphate . See [DB09413] for a description of phosphate's role in the body. |
| Pharmacodynamics | Glycerophosphate acts as a source of inorganic phosphate through hydrolysis . |
ADME / PK
| Absorption | Peak serum phosphate concentration is reached in 4h . |
|---|---|
| Half-life | Inorganic phosphate has a half-life of elimination of 2.06h . |
| Metabolism | Glycerophosphate is hydrolyzed to form inorganic phosphate . The extent of this reaction is dependent on serum alkaline phosphatase activity. |
| Route of elimination | Inorganic phosphate produced is eliminated in the urine . There may be a very small amount of glycerophosphate excreted in the urine unchanged. |
Formulation & handling
- Sodium glycerophosphate is a small molecule suitable for multiple routes including intravenous, intramuscular, oral, and parenteral administration.
- Its high water solubility facilitates formulation in aqueous injection solutions and oral preparations such as syrups and tablets.
- Handling considerations include maintaining solution stability, especially for injectable emulsions, and protection from moisture due to its solid state.
Regulatory status
| Lifecycle | The API's primary patents have expired in both the US and Canada, allowing for generic competition and established market presence. Consequently, the product is in a mature phase with multiple generic suppliers active in these regions. |
|---|
| Markets | US, Canada |
|---|
Supply Chain
| Supply chain summary | The manufacturing and supply landscape for sodium glycerophosphate includes multiple originator companies producing branded formulations primarily for the US and Canadian markets. Several branded products such as Glycophos and Olimel variants are available, indicating a diversified supply base. Patent expiries for these products suggest the presence of existing generic competition or potential for increased generic market entry. |
|---|
Sodium glycerophosphate is a type of Additives
Additives in the pharmaceutical API category refer to a group of chemical substances that are incorporated into pharmaceutical products to enhance their stability, functionality, or performance. These additives play a crucial role in ensuring the quality, safety, and efficacy of medications.
One common type of additive used in pharmaceuticals is preservatives. Preservatives are added to prevent microbial growth and maintain the integrity of the product throughout its shelf life. They help to safeguard against contamination and maintain the potency of the active pharmaceutical ingredient (API). Some commonly used preservatives include benzyl alcohol, phenol, and parabens.
Another important group of additives is antioxidants. Antioxidants are added to pharmaceutical formulations to prevent or delay the oxidation of APIs, which can lead to degradation and loss of potency. Examples of antioxidants commonly used in pharmaceuticals include ascorbic acid (vitamin C) and tocopherols (vitamin E).
In addition to preservatives and antioxidants, other additives like flavorings, colorants, and sweeteners may be incorporated into pharmaceutical products to improve their palatability and patient acceptability.
It is crucial to note that the use of additives in pharmaceuticals is strictly regulated by health authorities to ensure their safety and efficacy. Manufacturers must comply with stringent quality control standards and guidelines to guarantee the proper use and appropriate levels of additives in pharmaceutical products.
Overall, additives play a vital role in the pharmaceutical industry by enhancing the stability, functionality, and patient acceptability of medications. Their careful selection and incorporation contribute to the overall quality and effectiveness of pharmaceutical products.
Sodium glycerophosphate API manufacturers & distributors
Compare qualified Sodium glycerophosphate API suppliers worldwide. We currently have 4 companies offering Sodium glycerophosphate API, with manufacturing taking place in 4 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Acta minerals | Producer | Netherlands | Netherlands | BSE/TSE, CoA, GMP, MSDS | 67 products |
| Apollo Healthcare Resourc... | Distributor | Singapore | Singapore | BSE/TSE, CEP, CoA, EDMF/ASMF, FDA, GMP, ISO9001, JDMF, KDMF, MSDS, USDMF, WC | 200 products |
| Dr. Paul Lohmann GmbH & C... | Producer | Germany | Germany | CoA, EDMF/ASMF, GMP, MSDS, USDMF | 49 products |
| Tenatra Exports Private L... | Distributor | India | India | BSE/TSE, CoA, FDA, GMP, MSDS | 263 products |
When sending a request, specify which Sodium glycerophosphate API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Sodium glycerophosphate API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
